109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
Compounds and methods for modulating SCN2A
#902OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#903ISOLATED DOUBLE STRANDED DNA POLYNUCLEOTIDE
#904MODULATION OF AAV-BASED GENE EXPRESSION
#905Method of Treating Corneal Opacities and Scarring
#906METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE
#907SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
#908Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer
#909COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#910TGF-BETA THERAPEUTICS FOR AGE DISEASE
#911RNAi AGENT TARGETING MYD88 AND USE THEREOF
#912OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION
#913ANTISENSE OLIGOMERS TARGETING PCSK9
#914LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS
#915GENETIC THERAPY FOR GLAUCOMA AND OPTIC NEUROPATHIES
#916METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#917COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
#918Oligonucleotides reducing the amount of CD73 mRNA and CD73 protein expression
#919ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#920APPLICATION OF ANTISENSE OLIGONUCLEOTIDE TARGETING PBX1 PROMOTER REGION G-QUADRUPLEX IN PREPARATION OF MEDICINE FOR TREATING MELANOMA
#921PEPTIDE-NUCLEIC ACID COMPLEX HAVING BLOOD-BRAIN BARRIER PENETRATION ABILITY AND COMPOSITION COMPRISING SAME
#922Models of tauopathy
#923IN UTERO CRISPR-MEDIATED THERAPEUTIC EDITING OF GENES
#924Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infection
#925DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#926Target Ligand
#927Compositions, systems, and methods for regulation of hepatitis B virus through targeted gene repression
#928Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
#929OPTIMIZED ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS FOR TREATMENT OF PREECLAMPSIA AND OTHER ANGIOGENIC DISORDERS
#930ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9
#931METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
#932Compounds and methods for modulating ATXN1
#933Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#934Muscle targeting complexes and uses thereof for treating dystrophinopathies
#935PROTOPARVOVIRUS AND TETRAPARVOVIRUS COMPOSITIONS AND METHODS FOR GENE THERAPY
#936METHOD AND COMPOSITION FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, ASSOCIATED CONDITIONS AND SYMPTOMS
#937TREATMENT OF CANCER ASSOCIATED WITH VARIANT NOVEL OPEN READING FRAMES
#938TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES
#939ANTISENSE COMPOUNDS
#940COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH MULTIPLE ORGAN FAILURE
#941ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR THE TREATMENT OF PAIN
#942OLIGONUCLEOTIDE AND USE THEREOF AGAINST HEPATITIS B VIRUS AND HEPATITIS D VIRUS
#943PHARMACEUTICAL COMPOSITION
#944Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
#945EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#946Oligomers and oligomer conjugates
#947ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES
#948COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION
#949RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
#950OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
#951COMPOSITIONS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
#952COMPOUNDS AND METHODS FOR MODULATING SCN2A
#953TREATMENTS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
#954OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING
#955COMPLEMENT FACTOR B (CFB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#956INHIBITION OF miR-29b-3p TO ENHANCE NEURONAL SURVIVAL IN HUNTINGTON'S DISEASE
#957MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
#958Compositions and Methods Using SNRNA Components
#959METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS
#960ANTISENSE NUCLEIC ACID AND USE THEREOF
#961NUCLEIC ACID DUPLEXES
#962COMPOUNDS FOR MODULATING CHMP7
#963LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#964SIRT1-saRNA Compositions and Methods of Use
#965TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY
#966CASP8AP2 ANTAGONISTS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER
#967COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLS
#968OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES
#969bZIP TRANSCRIPTION FACTORS REGULATE CONVERSION OF NICOTINE TO NORNICOTINE
#970MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION
#971IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE
#972METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY
#973MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#974Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
#975TREATMENT OF OPTIC ATROPHY
#976ANTISENSE OLIGOMERS FOR TREATMENT OF DISEASE
#977MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS
#978TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS
#979METHODS FOR INHIBITING CHMP7 EXPRESSION IN NEURONAL CELLS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#980Method to Regulate ALOX12-AS1 IncRNA-Mediated Alteration of ALOX12 Protein and to Screen for Novel Drugs to Alter ALOX12 Protein Level
#981COMPOSITIONS AND METHODS FOR MODIFYING BACTERIAL GENE EXPRESSION
#982EXOSOMAL LOADING USING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES
#983COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#984SUMO Targeting Morpholinos as both Enhancers of Anti-Cancer Effects of Chemotherapeutic Treatments and Preventative Agents Against the Establishment of Chemoresistance
#985OLIGONUCLEOTIDES FOR APP MODULATION
#986MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF
#987METHODS FOR REGULATING BLOOD-CENTRAL NERVOUS SYSTEM (BLOOD-CNS) BARRIER AND USES THEREOF
#988MODIFIED FUNCTIONAL NUCLEIC ACID MOLECULES
#989TARGETING XIST AND RNA METHYLATION FOR X REACTIVATION THERAPY
#990PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION
#991Markers selectively deregulated in tumor-infiltrating regulatory T cells
#992COMPOUNDS AND METHODS FOR MODULATING PMP22
#993METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS
#994NOVEL COMPOUND AND APPLICATION THEREOF
#995Effect of Fuel Doping in ICF Targets
#996MODULATING SYNGAP
#997Compositions and Methods Targeting circ2082 for the Treatment of Cancer
#998Human XIST Antisense Oligonucleotides for X Reactivation Therapy
#999COMBINATION
#1000OLIGONUCLEIC ACID CONJUGATE
#1001METHODS FOR X CHROMOSOME REACTIVATION
#1002Methods of treating cholangiocarcinoma
#1003METHODS AND COMPOSITIONS FOR MACROPHAGE POLARIZATION
#1004USE OF SPLICE SWITCHING OLIGONUCLEOTIDES FOR EXON SKIPPING-MEDIATED KNOCKDOWN OF NF-KB COMPONENTS IN B CELLS
#1005TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS
#1006PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION
#1007COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#1008OLIGONUCLEOTIDE TREATMENT OF HEPATITIS B PATIENTS
#1009PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION
#1010NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE
#1011Morpholinos with Increased Delivery Efficiency
#1012RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION
#1013ANTISENSE OLIGONUCLEOTIDES FOR MODULATION OF LONG NONCODING RNAS
#1014DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#1015OLIGONUCLEOTIDES FOR MECP2 MODULATION
#1016OLIGONUCLEOTIDES
#1017METHODS FOR DE-CLOAKING CANCER FROM THE IMMUNE SYSTEM THROUGH DOWNREGULATION OF CANCER-PRODUCED PREGNANCY SPECIFIC GLYCOPROTEIN
#1018Methods of Protecting RNA
#1019Modifying the specificity of plant non-coding RNA molecules for silencing gene expression
#1020TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK)
#1021COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME
#1022METHODS FOR INTRACELLULAR DELIVERY AND ENHANCED GENE TARGETING
#1023OLIGONUCLEOTIDES FOR MLH1 MODULATION
#1024Compositions and methods of treating facioscapulohumeral muscular dystrophy
#1025METHODS OF TREATMENT OF INFLAMMATORY BOWEL DISEASES
#1026BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF
#1027ZBTB32 INHIBITORS AND USES THEREOF
#1028COMBINATION THERAPY WITH SEMAPHORIN-4D BLOCKADE AND HTT-LOWERING AGENT FOR TREATMENT OF HUNTINGTON'S DISEASE
#1029OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION
#1030OLIGOMERS HAVING BICYCLIC SCAFFOLD MOIETIES
#1031OLIGONUCLEOTIDES TARGETING XBP1
#1032COMPOUNDS FOR USE IN THE TREATMENT OF EPILEPSY
#1033COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
#1034METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS
#1035ANTISENSE RNA FOR TREATMENT OF SARS-ASSOCIATED CORONAVIRUS
#1036Compositions for modulating tau expression
#1037RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)
#1038ANTISENSE OLIGONUCLEOTIDES FOR RNA EDITING
#1039UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
#1040COMPOSITIONS AND METHODS FOR SIMULTANEOUSLY MODULATING EXPRESSION OF GENES
#1041Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#1042Modulators of PCSK9 Expression
#1043CELL LINE FOR USE IN PRODUCING RECOMBINANT ADENOVIRUSES
#1044COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS
#1045NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#1046RNA COMPRISING SECRETOMES AND METHODS OF THEIR USE
#1047COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME
#1048GENE THERAPIES FOR LYSOSOMAL DISORDERS
#1049POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
#1050IN VITRO NEPHROTOXICITY SCREENING ASSAY
#1051COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY
#1052Oligonucleotides for inducing paternal UBE3A expression
#1053COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER
#1054ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
#1055NUCLEIC ACID COMPLEX
#1056METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
#1057CYSTIC LYMPHANGIOMA TREATMENT DRUG
#1058METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS
#1059LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF
#1060TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS
#1061MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME
#1062COMPOSITIONS AND METHODS TO CONTROL INSECT PESTS
#1063METHODS FOR DIAGNOSING HUNTINGTON’S DISEASE
#1064Inhibition of lncExACT1 to Treat Heart Disease
#1065Compositions and methods of treating facioscapulohumeral muscular dystrophy
#1066MUCOPENETRATING FORMULATIONS
#1067COMBINATORY TREATMENT OF SMA WITH SARNA AND MRNA MODULATORS
#1068Oligonucleotide Agonists Targeting Progranulin
#1069METHODS FOR ENGINEERING NON-NEURONAL CELLS INTO NEURONS AND USING NEWLY ENGINEERED NEURONS TO TREAT NEURODEGENERATIVE DISEASES
#1070OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES
#1071Methods for using transcription-dependent directed evolution of AAV capsids
#1072Methods for using transcription-dependent directed evolution of AAV capsids
#1073MUSCLE-TARGETING COMPLEXES AND USES THEREOF
#1074Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
#1075MODIFYING THE SPECIFICITY OF PLANT NON-CODING RNA MOLECULES FOR SILENCING GENE EXPRESSION
#1076Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors
#1077RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF
#1078Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
#1079Compositions and methods of treating Facioscapulohumeral muscular dystrophy
#1080Single-stranded RNA-editing oligonucleotides
#1081ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES
#1082Methods of Prevention or Treatment of Alzheimer's Disease by Blocking or Decreasing STING Signaling Activation
#1083ANTISENSE OLIGONUCLEOTIDE INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE
#1084COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF
#1085SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2
#1086INHIBITORS OF LINE1 AND USES THEREOF
#1087COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION
#1088COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SCN2A
#1089METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF TRANSMEMBRANE CHANNEL-LIKE PROTEIN 1 (TMC1)
#1090MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1091ONCOGENIC TRIM37 IS A TARGETABLE EPIGENETIC DRIVER OF METASTASIS AND LINKS CHEMORESISTANCE AND METASTATIC FATE IN TRIPLE-NEGATIVE BREAST CANCER
#1092Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1093RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
#1094THERAPEUTICS FOR SYNGAP HAPLOINSUFFICIENCY
#1095COMPOSITION COMPRISING OSTEOPONTIN INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASE
#1096Modulators of APOL1 expression
#1097METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS
#1098MODULATION OF FACTOR 11 EXPRESSION
#1099Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors
#1100METHODS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF 2019-nCoV USING siRNAs AGAINST TGFB1 AND COX2
#1101SIRNA OF ANGPTL3 AND USE THEREOF
#1102Complement factor B (CFB) iRNA compositions and methods of use thereof
#1103TARGETING ZNF410 FOR FETAL HEMOGLOBIN INDUCTION IN BETAHEMOGLOBINOPATHIES
#1104METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
#1105Nucleic acid oligomers and uses therefor
#1106METHODS FOR TREATING GLIOBLASTOMA
#1107PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
#1108Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
#1109siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver Cancer
#1110OPA1 antisense oligomers for treatment of conditions and diseases
#1111Method and composition for early detection of malignancies
#1112Composition for regulating expression of PROX1 or expression of telomerase reverse transcriptase comprising activity regulator or method for screening telomerase reverse transcriptase regulator
#1113SMALL INTERFERING DEOXYRIBONUCLEIC ACID (SIDNA) AGAINST METALLO-BETA LACTAMASE GENE
#1114METHODS AND COMPOSITIONS FOR NEUROPROTECTION
#1115COMPOSITION AND METHODS FOR IDENTIFYING ANTISENSE GUIDE RNA FOR RNA EDITING
#1116THYCLOTIDES
#1117ENHANCEMENT OF THE PRODUCTION OF ADENOIDVIRUS-BASED GENETRANSFER VECTORS
#1118Compositions and methods for enhancing biomass productivity in plants
#1119COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
#1120ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR)
#1121METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES
#1122RNA EDITING INHIBITORS AND METHODS OF USE
#1123Selective inhibition of T follicular helper cells for treatment of autoimmune disorders
#1124METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1125METHODS AND COMPOSITIONS FOR TREATING EPILEPSY
#1126UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
#1127COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
#1128COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS
#1129METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#1130COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
#1131METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA DIRECTED MODULATION OF TRANSCRIPTION
#1132ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS
#1133INHIBITION OF POLYOMAVIRUS REPLICATION
#1134SPLICING-DEPENDENT TRANSCRIPTIONAL GENE SILENCING OR ACTIVATION
#1135Construct of self-circularization RNA
#1136Guanosine Analogues for Use in Therapeutics Polynucleotides
#1137THERAPEUTICS FOR HAPLOINSUFFICIENCY CONDITIONS
#1138NUCLEIC ACID MOLECULE FOR TREATING THROMBOCYTOPENIA AND APPLICATION THEREOF
#1139METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION
#1140SINGLE-STRANDED OLIGONUCLEOTIDE
#1141DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES
#1142SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION
#1143ANTISENSE THERAPEUTICS FOR BETACORONAVIRUS TREATMENT
#1144Compositions and Methods Using SNRNA Components
#1145MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#1146MULTI-CONJUGATES COMPRISING MULTIPLE LIGANDS
#1147SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS
#1148TGF-BETA INHIBITION, AGENTS AND COMPOSITION THEREFOR
#1149MODULATORS OF FOXP3 EXPRESSION
#1150COMPOSITION FOR PREVENTING OR TREATING DISEASE CAUSED BY MUSCLE LOSS, COMPRISING AGENT INHIBITING PHF20
#1151Treatment methods for muscular dystrophy
#1152METHOD FOR TREATING CYCLOPHILIN A ASSOCIATED DISEASES
#1153Compositions and Methods for Modifying Target RNAs
#1154NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE
#1155EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES
#1156Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
#1157OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9
#1158Thiomorpholino Oligonucleotides For The Treatment of Muscular Dystrophy
#1159USE OF SBDS INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1160Antisense oligonucleotides targeting alpha-synuclein and uses thereof
#1161Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels
#1162Treating metastatic cancer and model systems for metastatic disease
#1163VIRAL VECTOR FOR COMBINATION THERAPY
#1164PD-1-specific antisense oligonucleotide and its use in therapy
#1165COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT
#1166COMPOSITIONS AND METHODS FOR TREATING AND DETECTING CORONAVIRUS INFECTION
#1167ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1168COMPOSITIONS AND METHODS FOR REGULATION OF CELL ACTIVITY VIA MODULATION OF BETA-CYTOKINE ACTIVITY
#1169Compositions and Methods for Modulation of SMN2 Splicing in a Subject
#1170ANTAGONIST OF PCSK9
#1171Reducing intron retention
#1172USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
#1173Compositions and Methods for Genome Editing
#1174AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME
#1175Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
#1176COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH LOSS-OF-FUNCTION MUTATIONS IN SYNGAP1
#1177HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID
#1178CHANNEL MODULATORS
#1179METHODS AND COMPOSITIONS FOR TREATING ATAXIA TELANGIECTASIA
#1180ENGINEERED CIRCULAR POLYNUCLEOTIDES
#1181TARGETED RNA EDITING USING ENGINEERED ADENOSINE DEAMINASE ACTING ON TRNA (ADAT) SYSTEMS
#1182Manipulating Glycogen in Alzheimer’s Disease, Epilepsy, Traumatic Brain Injury, and ALS as a Treatment
#1183COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING
#1184BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF
#1185Double Stranded RNA Specifically Inhibiting Expression of IL-23 and Pharmaceutical Composition Comprising Same
#1186HYDROGEL-MATRIX ENCAPSULATED OLIGONUCLEOTIDES AND METHODS FOR FORMULATING AND USING ENCAPSULATED OLIGONUCLEOTIDES
#1187RNA-BASED ADJUVANT TO ENHANCE THE IMMUNE RESPONSE TO VACCINES AND THERAPEUTICS
#1188DOUBLE STRANDED RNA TARGETING ANGIOPOIETIN-LIKE 3 (ANGPTL-3) AND METHODS OF USE THEREOF
#1189MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
#1190ANTISENSE OLIGONUCLEOTIDE OF CALM2
#1191PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR
#1192MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#1193METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATING THERAPIES FOR TREATING CANCERS AND RELATED DISORDERS
#1194Composition for preventing or treating diseases caused by overexpression of chemokine CXCL1, containing death receptor inhibitor as active ingredient
#1195COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION
#1196THERAPEUTIC INTERFERING PARTICLES FOR CORONA VIRUS
#1197COMPOSITIONS AND METHODS OF INHIBITING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
#1198COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION
#1199ANTISENSE NUCLEIC ACIDS
#1200MODULATORS OF GROWTH HORMONE RECEPTOR